New hiv injectable drugs

Injection Drug Use and HIV Risk. Sharing needles, syringes, or other drug injection equipment (for example, cookers) puts people at risk for getting or transmitting HIV and other infections. About 1 in 10 . new HIV diagnoses in the United States . are attributed to injection drug use or male-to-male sexual contact and injection drug use. Risk

Twice-yearly injections of a new HIV prevention drug from Gilead Sciences helped reduce HIV infections by 96%, in today's bite-sized

The new drug England hopes will help it defeat HIV for good in less than a decade is the long-acting injectable form of established HIV drug

Injection drug use now accounts for an ever-growing proportion of people with HIV. On average 1 in 10 new HIV infections are caused by the sharing of needles.

HIV PrEP for Persons who Inject Drugs: Although no medication has an FDA indication for preventing HIV acquisition through injection drug use, the Bangkok Tenofovir Study showed that persons who inject drugs and take daily tenofovir DF for HIV PrEP experience a significant reduction in new HIV infections compared with persons taking placebo

Injection Drug Use and HIV Risk. Sharing needles, syringes, or other drug injection equipment (for example, cookers) puts people at risk for getting or transmitting HIV and other infections. About 1 in 10 . new HIV diagnoses in the United States . are attributed to injection drug use or male-to-male sexual contact and injection drug use. Risk

Men who inject drugs accounted for 4% (1,490) of new HIV diagnoses. Women who inject drugs accounted for 3% (1,161) of new HIV diagnoses. By race/ethnicity, Black/African American people and Hispanic/Latino people continue to be disproportionately affected by HIV. Racism, HIV stigma, discrimination, homophobia, poverty, and other barriers to

HIV diagnoses among people who inject drugs (PWID) In 2024, PWID accounted for 7% (2,651) of the 37,981 new HIV diagnoses. Men who inject drugs accounted for 4% (1,490) of new HIV diagnoses. Women who inject drugs accounted for 3% (1,161) of new HIV diagnoses.

Cabenuva, a new injectable formulation for HIV treatment, combines two HIV antiretroviral drugs, cabotegravir and rilpivirine.